癌診断技術の世界市場:ELISA、ELFA、PCR、NGS、免疫組織化学、マイクロアレイ、画像診断...市場調査レポートについてご紹介

【英文タイトル】Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 19)
2.1.1 Research Methodology Steps
2.1.2 Secondary and Primary Research Methodology
2.1.2.1 Secondary Research
2.1.2.2 Key Data From Secondary Sources
2.1.2.3 Primary Research
2.1.2.4 Key Industry Insights
2.1.5 Key Data From Primary Sources
2.1.6 Key Insights From Primary Sources
2.1.7 Market Size Estimation Methodology
2.1.8 Market Forecast Methodology
2.1.9 Market Data Validation and Triangulation
2.1.10 Assumptions for the Study

3 Executive Summary (Page No. – 32)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 38)
4.1 Global Cancer Diagnostics Market
4.2 Regional Snapshot of the Cancer Diagnostics Market
4.3 Cancer Diagnostics Market, By Technology (2015 vs. 2020)

5 Market Overview (Page No. – 42)
5.1 Key Findings
5.2 Introduction
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Cancer
5.3.1.2 Technological Advancements
5.3.1.3 Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
5.3.1.4 Growth in the Number of Private Diagnostic Centers
5.3.1.5 Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
5.3.1.6 Fda Support for Biomarker Development
5.3.1.7 Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
5.3.2 Restraints
5.3.2.1 High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
5.3.2.2 Shortage of Helium
5.3.2.3 High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
5.3.2.4 Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
5.3.2.5 Dearth of Skilled and Experienced Personnel
5.3.3 Opportunities
5.3.3.1 Personalized Medicine
5.3.3.2 Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
5.3.3.3 Companion Diagnostics
5.3.3.4 Improving Healthcare Infrastructure in Emerging Markets
5.3.3.5 Miniaturized and Technologically Advanced Devices
5.3.4 Challenges
5.3.4.1 Stringent Regulatory Guidelines
5.3.4.2 Hospital Budget Cuts A Key Challenge to Market Players
5.3.4.3 Increasing Adoption of Refurbished Diagnostic Imaging Systems

6 Global Cancer Diagnostics Market, By Technology (Page No. – 60)
6.1 Introduction
6.2 Platform-Based Diagnostics
6.2.1 Polymerase Chain Reaction (PCR)
6.2.2 in Situ Hybridization (ISH)
6.2.3 Immunohistochemistry (IHC)
6.2.4 Next-Generation Sequencing (NGS)
6.2.5 Microarrays
6.2.6 Flow Cytometry
6.2.7 Other Technologies
6.3 Instrument-Based
6.3.1 Diagnostic Imaging
6.3.1.1 Magnetic Resonance Imaging (MRI)
6.3.1.2 Computed Tomography (Ct)
6.3.1.3 Positron Emission Tomography (PET)
6.3.1.3.1 Standalone Positron Emission Tomography
6.3.1.3.2 Hybrid Positron Emission Tomography
6.3.1.4 Mammography
6.3.1.5 Ultrasound
6.3.2 Biopsies

7 Global Cancer Diagnostics Market, By Application (Page No. – 84)
7.1 Introduction
7.1.1 Breast Cancer
7.1.2 Lung Cancer
7.1.3 Colorectal Cancer
7.1.4 Melanoma
7.1.5 Other Cancers

8 Market, By End User (Page No. – 93)

9 Cancer Diagnostics Market, By Region (Page No. – 95)
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.1.1 Government Initiatives
9.2.1.2 Increase in Cancer Incidence
9.2.2 Canada
9.2.2.1 High Incidence of Cancer
9.2.2.2 Government Funding
9.3 Europe
9.3.1 Funding for Cancer Diagnostics Research
9.3.2 Eu-5 (U.K., Germany, France, Italy, Spain)
9.3.2.1 Strong Government Support
9.3.2.2 Research Collaborations
9.3.2.3 Increase in Diagnostic Imaging Centers
9.3.2.4 Rising Public and Private Investments
9.3.3 Rest of Europe (RoE)
9.3.3.1 Aging Population
9.3.3.2 Conferences Boosting Awareness
9.3.3.3 Government Investments in Russia
9.4 Asia
9.4.1.1 China
9.4.1.1.1 Expansion of International Players
9.4.1.1.2 Aging Population and Increasing Cancer Incidence
9.4.1.2 Japan
9.4.1.2.1 Aging Population and High Healthcare Expenditure in Japan
9.4.1.3 India
9.4.1.3.1 Increasing Focus of International Players on India
9.4.1.4 Rest of Asia
9.4.1.4.1 Presence of International Players Boosting Market Growth
9.5 Rest of the World (RoW)
9.5.1.1 Government Initiatives Boosting Demand for Cancer Diagnostics
9.5.1.2 Aging Population, Presence of International Players
9.5.1.3 Increase in Cancer Incidences and Rising Government Expenditure
9.5.1.4 Government Initiatives to Improve Healthcare Infrastructure

10 Competitive Landscape (Page No. – 138)
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 Collaborations/Agreements/Partnerships/Alliances
10.3.2 New Product Launches
10.3.3 Acquisitions
10.3.4 Expansion
10.3.5 Others

11 Company Profiles (Page No. – 153)
11.1 Introduction
11.3 Becton, Dickinson and Company
11.3.1 Business Overview
11.3.2 Product Portfolio
11.3.3 Key Strategy
11.3.4 Recent Developments
11.4 GE Healthcare (A Subsidiary of General Electric Company)
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Key Strategy
11.4.4 Recent Developments
11.5 Abbott
11.5.1 Business Overview
11.5.2 Product Portfolio
11.5.3 Key Strategy
11.5.4 Recent Developments
11.6 Roche
11.6.1 Business Overview
11.6.2 Product Portfolio
11.6.3 Key Strategy
11.6.4 Recent Developments
11.7 Thermo Fisher Scientific, Inc.
11.7.1 Business Overview
11.7.2 Thermo Fisher Scientific, Inc.: Company Snapshot
11.7.3 Product Portfolio
11.7.4 Key Strategy
11.7.5 Recent Developments
11.8 Agilent Technologies, Inc.
11.8.1 Business Overview
11.8.2 Agilent Technologies, Inc.: Company Snapshot
11.8.3 Product Portfolio
11.8.4 Key Strategy
11.8.5 Recent Developments
11.9 Illumina, Inc.
11.9.1 Business Overview
11.9.2 Product Portfolio
11.9.3 Key Strategy
11.9.4 Recent Developments
11.10 Siemens Healthcare
11.10.1 Business Overview
11.10.2 Product Portfolio
11.10.3 Key Strategy
11.10.4 Recent Developments
11.11 C.R. Bard, Inc.
11.11.1 Business Overview
11.11.2 Product Portfolio
11.11.3 Key Strategy
11.11.4 Recent Developments

12 Appendix (Page No. – 190)
12.1 Discussion Guide
12.2 Available Customizations
12.3 Related Reports
12.4 Introducing RT: Real-Time Market Intelligence


【レポート販売概要】

■ タイトル:癌診断技術の世界市場:ELISA、ELFA、PCR、NGS、免疫組織化学、マイクロアレイ、画像診断
■ 英文:Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
■ 発行日:2015年6月10日
■ 調査会社:MarketsandMarkets
■ 商品コード:MAM-MD-3480
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。